Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Huawei Technologies Co Ltd | 3,172 |
| 2 | Intel Corp | 1,060 |
| 3 | Everpure Inc | 707 |
| 4 | Samsung Electronics Co Ltd | 697 |
| 5 | Telefonaktiebolaget LM Ericsson AB | 665 |
| 6 | JPMorgan Chase Bank NA | 575 |
| 7 | Apple Inc | 567 |
| 8 | Amazon Technologies Inc | 516 |
| 9 | Microsoft Technology Licensing LLC | 492 |
| 10 | China Mobile Communications Group Co Ltd | 464 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | H04L | 28,272 | |
| 2 | G06F | 13,759 | |
| 3 | H04W | 11,553 | |
| 4 | A61K | Medicinal preparations | 6,165 |
| 5 | A61P | Therapeutic activity (drug indications) | 5,780 |
| 6 | C12N | Microorganisms, enzymes | 4,999 |
| 7 | Y02D | 4,422 | |
| 8 | H04N | 4,145 | |
| 9 | G06Q | 3,537 | |
| 10 | G06N | 3,251 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof | 2000 | Inspire Pharmaceuticals Inc | 59 |
| Uridine 5'-diphosphate and analogs useful for treating lung diseases | 2000 | Inspire Pharmaceuticals Inc | 58 |
| Method of treating lung diseases with uridine 5′-diphosphate and analogs thereof | 2002 | Inspire Pharmaceuticals Inc | 32 |
| URIDINE DIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | 2013 | DONG, Jinghui | 26 |
| URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | 2014 | HAYDON, PHILIP, G. | 15 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Adenosine and Purinergic Signaling | 7 |
| 2 | Glycosylation and Glycoproteins Research | 6 |
| 3 | Diet, Metabolism, and Disease | 3 |
| 4 | Biochemical Analysis and Sensing Techniques | 2 |
| 5 | Biochemical and Molecular Research | 2 |
| 6 | Carbohydrate Chemistry and Synthesis | 2 |
| 7 | Advanced MRI Techniques and Applications | 1 |
| 8 | Amino Acid Enzymes and Metabolism | 1 |
| 9 | Antifungal resistance and susceptibility | 1 |
| 10 | Antimicrobial Resistance in Staphylococcus | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Barbara Imperiali | Massachusetts Institute of Technology | 10 |
| 2 | Bernard Robaye | Université Libre de Bruxelles | 8 |
| 3 | Bilha Fischer | Bar-Ilan University | 6 |
| 4 | Bing Du | East China Normal University | 6 |
| 5 | David Erlinge | Lund University | 6 |
| 6 | Eduardo R. Lazarowski | University of North Carolina at Chapel Hill | 6 |
| 7 | Kenneth A. Jacobson | National Institute of Diabetes and Digestive and Kidney Diseases | 6 |
| 8 | André Terzic | Mayo Clinic | 5 |
| 9 | D.A.R. Sanders | University of Saskatchewan | 5 |
| 10 | William Pendergast | Inspire Institute | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis | 2007 | 811 | Adenosine and Purinergic Signaling |
| The Arabidopsis UDP‐glycosyltransferases UGT79B2 and UGT79B3, contribute to cold, salt and drought stress tolerance via modulating anthocyanin accumulation | 2016 | 599 | Photosynthetic Processes and Mechanisms |
| A little sugar goes a long way: The cell biology of O-GlcNAc | 2015 | 583 | Glycosylation and Glycoproteins Research |
| Higher plant glycosyltransferases. | 2001 | 515 | Plant tissue culture and regeneration |
| Structure of a flavonoid glucosyltransferase reveals the basis for plant natural product modification | 2006 | 469 | Microbial Natural Products and Biosynthesis |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Uridine Diphosphate?
What are the primary research topics associated with Uridine Diphosphate?
What are notable patents related to Uridine Diphosphate treatments?
How has publication and patent activity around Uridine Diphosphate changed in recent years?
Who are leading researchers studying Uridine Diphosphate?